Access Bio, Inc. (KOSDAQ: 950130)

Market Cap	219.44B
Revenue (ttm)	101.33B
Net Income (ttm)	-15.65B
Shares Out	33.81M
EPS (ttm)	-454.32
PE Ratio	n/a
Forward PE	n/a
Dividend	823.00 (13.02%)
Ex-Dividend Date	n/a

Volume	288,235
Open	6,310.00
Previous Close	6,320.00
Day's Range	6,310.00 - 6,680.00
52-Week Range	6,150.00 - 14,340.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Access Bio

Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; and molecular diagnostic solu...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2002
• Employees: 101
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950130